GlassScriptPhysician profile
Frank J Rabito
NPI 1821080367
$12,865.94
in general payments reported to CMS, 2019-2025
37 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,507 · 2020: $1,905 · 2021: $2,044 · 2022: $1,974 · 2023: $2,647 · 2024: $2,568 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,424 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,423.83 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,287.58 | 2019-2024 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $1,626.97 | 2019-2024 | Veklury |
| Paratek Pharmaceuticals, INC. | $1,240.79 | 2019-2024 | Nuzyra |
| Insmed, INC. | $1,014.25 | 2019-2024 | Arikayce |
| Merck Sharp & Dohme LLC | $960.18 | 2019-2024 | Dificid, Delstrigo, Pifeltro |
| Abbvie INC. | $813.54 | 2021-2024 | |
| Theratechnologies INC. | $598.98 | 2019-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Janssen Biotech, INC. | $465.40 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $388.18 | 2019-2024 | Serostim |
| Melinta Therapeutics, LLC | $383.75 | 2019-2024 | Orbactiv, Kimyrsa, Vabomere |
| Stryker Corporation | $340.90 | 2023-2025 | Ortholoc 2 Lapifuse, Asnis |
| Organogenesis INC. | $331.74 | 2019-2023 | Puraply |
| Astellas Pharma US INC | $319.07 | 2019-2024 | Cresemba |
| Napo Pharmaceuticals INC | $236.24 | 2019-2024 | Mytesi |
| Allergan, INC. | $219.29 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $216.68 | 2022-2024 | Fetroja |
| Pfizer INC. | $202.52 | 2020-2024 | |
| Amarin Pharma, INC. | $187.89 | 2020-2022 | |
| Hydrofera LLC | $172.63 | 2024 | Hydrofera Blue |
| Kerecis Limited | $158.81 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Mayne Pharma Commercial LLC | $151.75 | 2019-2022 | |
| Mimedx Group, INC. | $130.87 | 2024 | |
| Nabriva Therapeutics, Plc | $51.41 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $49.40 | 2024 | Xacduro |
| Smith+Nephew, INC. | $48.70 | 2023-2024 | Collagenase Santyl, Iodosorb Ointment 40g USA, Regranex |
| Pharming Healthcare, INC. | $39.60 | 2024 | Ruconest |
| Kowa Pharmaceuticals America, INC. | $36.54 | 2021-2022 | |
| Reprise Biomedical, INC. | $28.54 | 2024 | Miro3d |
| Vyera Pharmaceuticals, LLC | $25.38 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.25 | 2021 | |
| Accelerate Diagnostics INC. | $19.65 | 2020 | |
| Horizon Therapeutics Plc | $19.44 | 2023 | Krystexxa |
| Ferring Pharmaceuticals INC. | $17.21 | 2024 | Rebyota |
| Tetraphase Pharmaceuticals, INC. | $16.79 | 2019 | |
| Philips North America LLC | $15.12 | 2023 | |
| Tactile Systems Technology INC | $14.68 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Rabito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.